HARMONIA is an international, multicenter, randomized, open-label and phase III study.

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.

This is a Phase III open-label study to assess if Camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence.

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/?HER2- Early Breast Cancer (CAMBRIA-2)

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy.

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combinations of HER2-directed therapies as a treatment after surgery.

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery after preoperative chemotherapy and HER2-targeted therapy.